Linher et al. found that STAT3 activation is coupled with increased system Xc− activity in human breast cancer cells and proposed that targeting system Xc− together with STAT3/5 inhibitors may improve therapeutic anticancer effects [30, 31]. Here, STAT3 is linked to breast cancer.